As of Friday close, BioNTech SE’s (NASDAQ:BNTX) stock was down -$2.86, moving down -2.53 percent to $110.36. The average number of shares traded per day over the past five days has been 657,740 shares. 3 times new highs have been achieved over the past 5 days, with a $3.44 gain in that time frame. In the last twenty days, the average volume was 831,055, while in the previous 50 days, it was 676,250.
Since last month, BNTX stock rose 2.45%. Shares of the company fell to $95.50 on 08/07/23, the lowest level in the past month. A 52-week high of $188.99 was reached on 01/06/23 after having rallying from a 52-week low of $95.50. Since the beginning of this year, BNTX’s stock price has dropped by -26.53% or -$39.86, and marked a new high 2 times. However, the stock has declined by -41.60% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, BioNTech SE (BNTX) has a P/E ratio of about 5.73. The stock’s beta is 0.19. Besides these, the trailing price-to-sales (P/S) ratio of 2.59, the price-to-book (PB) ratio of 1.22, and the price-to-cash flow ratio of 2.71 may also be considered.
Financial Health
In the recent quarter, BioNTech SE’s quick ratio stood at 10.30, while its current ratio was 10.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 0.01, and the total debt-to-equity ratio was 0.01. On the profitability front, the trailing twelve-month gross margin is 87.00% percent. In the recent year, EBITDA margin amounted to 88.49%, whereas operating margins totaled 62.80%. Based on annual data, BNTX earned $15.08 billion in gross profit and brought in $18.24 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 45.00%. Return on equity (ROE) for the past 12 months was 22.30%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. During the quarter, the company generated -$578.9 million in EBITDA. The liabilities of BioNTech SE were 2.53 billion at the end of its most recent quarter, and its total debt was $205.7 million.
Technical Picture
This quick technical analysis looks at BioNTech SE’s (BNTX) price momentum. With a historical volatility rate of 38.32%, the RSI 9-day stood at 57.76% on 18 August.
With respect to its five-day moving average, the current BioNTech SE price is up by +3.22% percent or $3.44. At present, BNTX shares trade +1.63% above its 20-day simple moving average and -10.71% percent below its 100-day simple moving average. However, the stock is currently trading approximately +0.87% above its SMA50 and -19.82% below its SMA200.
Stochastic coefficient K was 89.25% and Stochastic coefficient D was 84.68%, while ATR was 3.87. Given the Stochastic reading of 82.85% for the 14-day period, the RSI (14) reading has been calculated as 55.51%. As of today, the MACD Oscillator reading stands at 3.26, while the 14-day reading stands at 4.15.
Analyst Ratings
HSBC Securities launched its rating on BioNTech SE (NASDAQ: BNTX) to a Buy in a note to investors on July 14, 2023. BioNTech SE (BNTX) has been rated Overweight by analysts. According to 0 brokerage firms, BNTX is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate BioNTech SE stock as buy, with 11 recommending it as overweight.
With a median target price of $140.30, the current consensus forecast for the stock is $91.35 – $236.29. Based on these forecasts, analysts predict BioNTech SE (BNTX) will achieve an average price target of $142.10.
